Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, and markets prescription medicines for serious diseases. The company focuses on key therapeutic areas including oncology, hematology, immunology, and cardiovascular disease. It is widely recognized for its blockbuster drugs, such as the blood thinner Eliquis and the cancer immunotherapy Opdivo. Bristol-Myers Squibb operates globally, with the United States accounting for the majority of its total revenue. The company has significantly expanded its portfolio and research pipeline through strategic acquisitions, most notably its $74 billion purchase of Celgene in 2019, which bolstered its leadership in hematology. Its products are primarily distributed to wholesalers, retail pharmacies, hospitals, and government entities worldwide.
